Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia

Bibliography

• Chan SW. Global perspective of burden of family caregivers for persons with schizophrenia. Arch Psychiatr Nurs 2011;25:339-49
   PubMed Web of Science ®Google Scholar
• Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-93
   PubMed Web of Science ®Google Scholar
• Van der Velde CD. Variability in schizophrenia: reflection of a regulatory disease. Arch Gen Psychiatry 1976;33:489-96
   PubMedGoogle Scholar
• Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. The primary and secondary symptoms of schizophrenia: current and future management. Suppl Curr Psychiatry 2011;10:S5-9
   Google Scholar
• Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72
   PubMed Web of Science ®Google Scholar
• Corriss DJ, Smith TE, Hull JW, et al. Interactive risk factors for treatment adherence in a chronic psychotic disorders population. Psychiatry Res 1999;89:269-74
   PubMed Web of Science ®Google Scholar
• Marder SR, Mebane A, Chien CP, et al. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 1983;140:470-2
   PubMedGoogle Scholar
• Kim S, Solari H, Weiden PJ, Bishop JR. Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults. Patient Prefer Adherence 2012;6:533-45
   PubMed Web of Science ®Google Scholar
• Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev 2012;6:CD008296
   PubMed Web of Science ®Google Scholar
• Carter NJ. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia. Drugs 2012;72:1137-60
   PubMed Web of Science ®Google Scholar
• Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181-9
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011;364:842-51
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013;74:568-75
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74:957-65
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2014;40:192-213
   PubMed Web of Science ®Google Scholar
• Bitter I, Katona L, Zambori J, et al. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol 2013;23:1383-90
   PubMed Web of Science ®Google Scholar
• Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010;35:2367-77
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-96
   PubMed Web of Science ®Google Scholar
• Zhu B, Scher-Svanum H, Shi L, et al. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv 2008;9:315-17
   Google Scholar
• Macfadden W, Ma YW, Thomas HJ, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry 2010;7:23-31
   PubMedGoogle Scholar
• Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry 2007;191:131-9
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol 2013;28:57-66
   PubMed Web of Science ®Google Scholar
• Prikryl R, Prilrylova KH, Vrzalova M, Ceskova E. Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective. Schizophr Res Treatment 2012;2012:764769
   PubMedGoogle Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011;127:83-92
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9
   PubMed Web of Science ®Google Scholar
• Lafeuille MH, Laliberte-Auger F, Lefebvre P, et al. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 2013;13:221
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General Study of Schizophrenia (CGS). Schizophr Res 2012;134:187-94
   PubMed Web of Science ®Google Scholar
• Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl 2009;52:S13-19
   PubMedGoogle Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Zhang JP, Gallego JA, Robinson DG, et al. Efficacy and safety of individual second-generation versus first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2013;16:1205-18
   PubMed Web of Science ®Google Scholar
• Perez-Iglesias R, Mata I, Martinez-Garcia O, et al. Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. J Clin Psychopharmacol 2012;32:804-8
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Cleton A, Rossenu S, et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol (Oxf) 2010;24:1011-18
   PubMed Web of Science ®Google Scholar
• Park EJ, Amatya S, Kim MS, et al. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res 2013;36:651-9
   PubMed Web of Science ®Google Scholar
• Chue P, Chue J. A review of paliperidone palmitate. Expert Rev Neurother 2012;12:1383-97
   PubMed Web of Science ®Google Scholar
• Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 2009;48:585-600
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals, Inc. INVEGAR SUSTENNAR (paliperidone palmitate) extended-release injectable suspension, for intramuscular use. Janssen Pharmaceuticals, Inc., Titusville, NJ; 2012
   Google Scholar
• Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235-4
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35:2072-82
   PubMed Web of Science ®Google Scholar
• Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010;13:635-47
   PubMed Web of Science ®Google Scholar
• Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol (Oxf) 2011;25:685-97
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116:107-17
   PubMed Web of Science ®Google Scholar
• Nicholl D, Nasrallah H, Nuamah I, et al. Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention. Curr Med Res Opin 2010;26:1471-84
   PubMed Web of Science ®Google Scholar
• Kozma CM, Slaton T, Dirani R, et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). Curr Med Res Opin 2011;27:1603-11
   PubMed Web of Science ®Google Scholar
• Bossie CA, Sliwa JK, Ma YW, et al. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry 2011;11:79
   PubMed Web of Science ®Google Scholar
• Sliwa JK, Bossie CA, Fu DJ, et al. Onset of efficacy on specific symptoms domains with long-acting injectionable palperidone palmitate in subjects with schizophrenia. Poster presented at: 14th International Congress on Schizophrenia Research; 21 – 25 April 2013; Orlando, FL
   Google Scholar
• Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218-26
   PubMed Web of Science ®Google Scholar
• Gopal S, Pandina G, Lane R, et al. A post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov Clin Neurosci 2011;8:26-33
   PubMedGoogle Scholar
• Alphs L, Fu DJ, Sliwa JK, et al. Onset of efficacy in schizophrenia symptom domains with long-acting injectable paliperidone palmitate vs oral risperidone. Poster presented at: American Psychiatric Association 166th Annual Meeting; 18 – 22 May 2013; San Francisco, CA
   Google Scholar
• Weiden PJ, Schooler NR, Weedon JC, et al. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009;70:1397-406
   PubMed Web of Science ®Google Scholar
• Potkin S, Bera R, Zubek D, Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 2013;13:261
   PubMed Web of Science ®Google Scholar
• Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007;21:441-8
   PubMed Web of Science ®Google Scholar
• Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007;22:275-82
   PubMed Web of Science ®Google Scholar
• Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009;164:6-10
   PubMedGoogle Scholar
• Hamann J, Cohen R, Leucht S, et al. Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiatry 2005;162:2382-4
   PubMed Web of Science ®Google Scholar
• Hamann J, Cohen R, Leucht S, et al. Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry 2007;68:992-7
   PubMed Web of Science ®Google Scholar
• Hamann J, Mendel RT, Fink B, et al. Patients’ and psychiatrists’ perceptions of clinical decisions during schizophrenia treatment. J Nerv Ment Dis 2008;196:329-32
   PubMed Web of Science ®Google Scholar
• McNeil BJ, Pauker SG, Sox HC Jr, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med 1982;306:1259-62
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Roma RS, Velligan DI, et al. The challenge of offering long acting antipsychotic therapies: A discourse analysis of psychiatrist recommendations of injectable therapy to patients with schizophrenia. Presented at the 2011 US Psychiatric and Mental Health Congress; 7 – 10 November 2011; Las Vegas, NV
   Google Scholar
• Lin J, Wong B, Offord S, Mirski D. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Res 2013;40:355-66
   PubMed Web of Science ®Google Scholar
• Offord S, Wong B, Mirski D, et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 2013;16:231-9
   PubMedGoogle Scholar
• Kozielska M, Pilla RV, Johnson M, et al. Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia. Schizophr Res 2013;146:53-8
   PubMedGoogle Scholar
• Alphs L, Benedetti F, Fleischhacker WW, Kane JM. Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol 2012;15:1003-14
   PubMed Web of Science ®Google Scholar
• Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 2010;36:504-9
   PubMed Web of Science ®Google Scholar
• Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry 2012;73:856-64
   PubMed Web of Science ®Google Scholar
• Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25:247-56
   PubMed Web of Science ®Google Scholar
• Takahashi N, Takahashi M, Saito T, et al. Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia. Neuropsychiatr Dis Treat 2013;8:1889-98
   PubMed Web of Science ®Google Scholar